证券代码：688566 证券简称：吉贝尔 公告编号：2025-012 江苏吉贝尔药业股份有限公司 第四届监事会第十四次会议公告 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 根据《公司法》《公司章程》《公司监事会议事规则》等有关规定，公司监事 会就 2024 年度主要工作回顾及 2025 年度主要工作安排编制了《江苏吉贝尔药业 股份有限公司 2024 年度监事会工作报告》。 表决情况：3 票同意、0 票反对和 0 票弃权。 表决结果：通过。 本议案尚需提交公司股东大会审议。 （二）审议通过《公司 2024 年度财务决算报告》 根据《公司法》《公司章程》等有关规定，公司董事会根据 2024 年度公司整 体经营情况编制了《江苏吉贝尔药业股份有限公司 2024 年度财务决算报告》。 表决情况：3 票同意、0 票反对和 0 票弃权。 江苏吉贝尔药业股份有限公司（以下简称"公司"）第四届监事会第十四次 会议于 2025 年 4 月 3 日以书面方式发出通知，于 2025 年 4 月 14 日在公司会议 室召开 ...

证券代码：688566 证券简称：吉贝尔 公告编号：2025-013 江苏吉贝尔药业股份有限公司 2024 年度利润分配预案公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股分配比例：每 10 股派发现金红利人民币 2.60 元（含税），不送 红股，不进行资本公积金转增股本。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体 日期将在权益分派实施公告中明确。如在本公告披露之日起至实施权益分派 股权登记日期间公司总股本发生变动的，公司拟维持分配总额不变，相应调 整每股分配比例，并将另行公告具体调整情况。 本次利润分配符合相关法律法规及《公司章程》的规定，不触及《上 海证券交易所科创板股票上市规则》第 12.9.1 条第一款第（八）项规定的可 能被实施其他风险警示的情形。 一、利润分配方案内容 （一）利润分配方案的具体内容 经信永中和会计师事务所（特殊普通合伙）审计，江苏吉贝尔药业股份 有限公司（以下简称"公司"）2024 年度实现归属于上市公司股东的净利润 为 219,327,779.08 ...

Revenue and Profitability - Revenue for Q1 2025 was CNY 201.80 million, a 3.90% increase compared to CNY 194.23 million in the same period last year[4] - Net profit attributable to shareholders decreased by 5.68% to CNY 49.53 million from CNY 52.51 million year-on-year[4] - Basic and diluted earnings per share decreased by 10.71% to CNY 0.25 from CNY 0.28 in the same period last year[4] - Total operating revenue for Q1 2025 was CNY 201.80 million, a 3.6% increase from CNY 194.23 million in Q1 2024[17] - Net profit for Q1 2025 was CNY 49.45 million, a decrease of 5.6% compared to CNY 52.43 million in Q1 2024[18] - Basic and diluted earnings per share for Q1 2025 were CNY 0.25, down from CNY 0.28 in Q1 2024[19] Cash Flow and Investments - Operating cash flow decreased significantly by 46.29% to CNY 43.99 million, primarily due to a reduction in bank acceptance bill discounts[4][7] - Cash flow from operating activities generated a net amount of CNY 43.99 million in Q1 2025, significantly lower than CNY 81.90 million in Q1 2024[21] - Cash flow from investing activities resulted in a net outflow of CNY 276.86 million in Q1 2025, compared to a net outflow of CNY 303.49 million in Q1 2024[22] - Cash and cash equivalents decreased to CNY 627,550,120.58 from CNY 847,480,374.78, representing a decline of approximately 26%[13] - Cash and cash equivalents at the end of Q1 2025 totaled CNY 626.93 million, an increase from CNY 482.41 million at the end of Q1 2024[22] Research and Development - Total R&D investment increased by 64.28% to CNY 15.93 million, representing 7.89% of revenue, up from 4.99% in the previous year[5][7] - Research and development expenses decreased to CNY 7.84 million in Q1 2025, down from CNY 9.70 million in Q1 2024[17] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2.55 billion, a 0.87% increase from CNY 2.53 billion at the end of the previous year[5] - The company's current assets totaled CNY 1,310,717,373.59, slightly up from CNY 1,304,434,022.07, indicating a marginal increase of about 0.25%[13] - The company's total liabilities decreased to CNY 246,341,993.37 from CNY 273,675,274.92, a reduction of about 10%[15] - The company's long-term equity investments rose to CNY 83,878,587.70 from CNY 79,791,620.21, reflecting an increase of about 5%[14] - The company's inventory increased to CNY 35,139,081.55 from CNY 30,697,954.49, showing a growth of approximately 14.5%[14] - The company's short-term borrowings increased to CNY 23,754,693.09 from CNY 20,828,108.65, indicating an increase of about 14%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,292[9] - The top shareholder, Zhenjiang Zhongtian Investment Consulting Co., Ltd., holds 27.28% of the shares, totaling 54.40 million shares[9] - Shareholder equity attributable to shareholders increased by 2.20% to CNY 2.30 billion from CNY 2.25 billion year-on-year[5] - The total equity attributable to shareholders increased to CNY 2,298,167,640.82 from CNY 2,248,637,420.86, marking an increase of approximately 2.2%[15] Future Outlook - The company reported non-recurring gains of CNY 219,450.08, primarily from government subsidies and financial asset disposals[7] - The company is focusing on new product development and market expansion strategies to enhance future growth prospects[16] - The company's net profit for the first quarter of 2025 will be reported in the upcoming earnings release, with expectations of growth based on previous performance trends[16]

Dividend Distribution - The company plans to distribute a cash dividend of RMB 2.60 per 10 shares, totaling RMB 51,852,024.90 (including tax) based on a total share capital of 199,430,865 shares[7]. - The total cash dividends for the year 2024 are expected to reach RMB 154,802,074.70 (including tax) if the proposed distribution plan is approved[8]. - The board of directors has authorized the formulation of a specific mid-term profit distribution plan for 2024[8]. Financial Performance - The company's operating revenue for 2024 reached ¥896,534,453.46, representing a 4.14% increase compared to ¥860,933,244.79 in 2023[24]. - The net profit attributable to shareholders for 2024 was ¥219,327,779.08, a slight increase of 0.11% from ¥219,087,891.18 in 2023[24]. - The net profit after deducting non-recurring gains and losses was ¥215,090,754.66, up 2.85% from ¥209,137,599.61 in 2023[24]. - The net cash flow from operating activities increased by 34.98% to ¥215,293,605.06 in 2024, compared to ¥159,500,018.77 in 2023[24]. - The company's total assets as of the end of 2024 were ¥2,527,540,551.74, reflecting a 14.39% increase from ¥2,209,668,213.23 at the end of 2023[24]. - The net assets attributable to shareholders increased by 18.05% to ¥2,248,637,420.86 at the end of 2024, compared to ¥1,904,838,829.13 at the end of 2023[24]. - The basic earnings per share for 2024 were ¥1.13, a decrease of 3.42% from ¥1.17 in 2023[25]. - The weighted average return on equity decreased to 10.51% in 2024, down from 12.22% in 2023, a reduction of 1.71 percentage points[25]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 7.85% in 2024, up from 6.48% in 2023[25]. - The company invested a total of 70.41 million yuan in R&D, representing a 26.25% increase year-on-year[36]. - The company has established a comprehensive drug development system, covering all stages from compound screening to industrialization, supported by a professional R&D team[68][69]. - The company is actively engaged in the research and development of innovative drugs for conditions such as depression and tumors[38]. - The company is developing a new antidepressant drug JJH201501, which has completed Phase II clinical trials and is currently in Phase III trials, showing significant efficacy and good safety profile[60]. - The anticancer drug JJH201601 has completed Phase I clinical trials and is now in Phase IIa trials, demonstrating superior tumor suppression effects compared to imported docetaxel injections[61]. - The company is developing a new diabetes treatment using mulberry leaf extracts, with quality standards established and ongoing research on extraction and stability[65]. Product Development and Innovation - The company is advancing multiple new drug projects, including JJH201601 and JJH201701, with significant progress reported[35]. - The company has developed multiple deuterated compounds, including new drugs for depression (JJH201501), gastric acid (JJH201701), gallbladder inflammation and gallstones (JJH201801), and diabetes (JJH202301)[97]. - The company has established various research centers and innovation platforms, contributing to its ongoing technical advancements and product development[114]. - The company’s product range includes treatments for various conditions, such as hypertension, immune enhancement, and joint diseases, catering to diverse market needs[111]. Market and Competitive Landscape - The global pharmaceutical market is projected to reach $1,711.4 billion by 2025, with a CAGR of 5.70% from 2020 to 2025, and $2,105.9 billion by 2030, with a CAGR of 4.20% from 2025 to 2030[76]. - China's pharmaceutical market is expected to reach ¥228.73 billion by 2025, with a CAGR of 9.60% from 2020 to 2025, and ¥299.11 billion by 2030[77]. - The pharmaceutical industry is characterized by high technical, financial, and talent requirements, with significant barriers to entry due to long development cycles and high investment costs[82][83]. - The company aims to expand its market presence and sales scale through optimized marketing strategies and new product development[74]. Corporate Governance - The company has confirmed that all directors are present at the board meeting[5]. - The company has not disclosed any special arrangements for corporate governance[10]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with corporate governance standards[184]. - The company has established a supervisory board consisting of three supervisors, including one employee representative supervisor, ensuring compliance with relevant laws and regulations[185]. Risk Management - The company has outlined various risks in its operations, which are detailed in the management discussion and analysis section[4]. - There are no non-operating fund occupations by controlling shareholders or related parties reported[11]. - The company is closely monitoring macroeconomic risks and is prepared to implement measures to mitigate potential impacts on business development[126]. - The company faces risks related to the potential imitation of its main products, particularly Licorice tablets, which could impact its exclusive production status[119]. Talent and Human Resources - The company has established a comprehensive talent training system to support its strategic development, ensuring a stable and effective human resource base[37]. - The number of R&D personnel increased to 122, representing 9.19% of the total workforce, up from 7.40% in the previous period[110]. - The total compensation for R&D personnel was 22,040,538.32 RMB, with an average salary of 180,660.15 RMB, a decrease from 198,780.07 RMB in the prior period[110]. - The company emphasizes the importance of retaining core technical personnel, as their expertise is crucial for ongoing innovation and development[122]. Future Outlook - Future outlook indicates a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[193]. - The company plans to enhance its digital marketing efforts, aiming for a 40% increase in online sales channels[192]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[192]. - The company is committed to upgrading production capacity and enhancing digital transformation through new project implementations[181].

前十大流通股东累计持有： 15006.8万股，累计占流通股比： 75.24%，较上期变化： 119.06万股。 一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 1.1300 | 1.1700 | -3.42 | 0.8300 | | 每股净资产（元） | 11.28 | 10.07 | 12.02 | 9.03 | | 每股公积金(元) | 6.52 | 5.72 | 13.99 | 5.58 | | 每股未分配利润(元) | 3.26 | 2.85 | 14.39 | 1.98 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 8.97 | 8.61 | 4.18 | 6.55 | | 净利润(亿元) | 2.19 | 2.19 | 0 | 1.55 | | 净资产收益率(%) | 10.51 | 12.22 | -13.99 | 9.36 | 数据四舍五入，查看更多财务数据>> 二、前10 ...

证券代码：688566 证券简称：吉贝尔 公告编号：2025-021 江苏吉贝尔药业股份有限公司 2025 年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 4 月 14 日 （二） 股东大会召开的地点：江苏省镇江市高新技术产业开发园区公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 98 | | --- | --- | | 普通股股东人数 | 98 | | 2、出席会议的股东所持有的表决权数量 | 138,000,778 | | 普通股股东所持有表决权数量 | 138,000,778 | | 3、出席会议的股东所持有表决权数量占公司表决权数 | 69.1973% | | 量的比例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比 | 69.1973% | | 例（%） ...

致：江苏吉贝尔药业股份有限公司 北京市金杜（南京）律师事务所（以下简称本所）接受江苏吉贝尔药业股 份有限公司（以下简称公司）委托，根据《中华人民共和国证券法》《中华人 民共和国公司法》、中国证券监督管理委员会（以下简称中国证监会）《上市 公司股东会规则（2025 修订）》（以下简称《股东会规则》）等中华人民共和 国境内（以下简称中国境内，为本法律意见书之目的，不包括中华人民共和国 香港特别行政区、中华人民共和国澳门特别行政区和中华人民共和国台湾地区） 现行有效的法律、行政法规、规章及规范性文件和现行有效的公司章程有关规 定，指派律师出席了公司于 2025 年 4 月 14 日召开的 2025 年第一次临时股东 大会（以下简称本次股东大会），并就本次股东大会相关事项出具本法律意见 书。 北京市金杜（南京）律师事务所 关于江苏吉贝尔药业股份有限公司 2025 年第一次临时股东大会 之法律意见书 在本法律意见书中，本所仅对本次股东大会召集和召开的程序、出席本次 股东大会人员资格和召集人资格及表决程序、表决结果是否符合有关法律、行 政法规、《股东会规则》和《公司章程》的规定发表意见，并不对本次股东大 会所审议的议案内 ...

证券代码：688566 证券简称：吉贝尔 公告编号：2025-011 江苏吉贝尔药业股份有限公司 监事会关于公司2025年限制性股票激励计划首次授予激励 对象名单审核及公示情况的说明 2、公司于2025年3月29日至2025年4月7日在公司内部对本次首次授予激励对象的姓名和职务进行了公 示，公示期间共计10天，公司员工可在公示有效期内向监事会提出意见。截至公示期满，公司未收到任 何与本次激励计划相关的异议。 二、核查意见 公司监事会根据《管理办法》《激励计划（草案）》的规定，对公司2025年限制性股票激励计划首次授 予的激励对象名单进行了核查，并发表核查意见如下： 3、本次激励计划首次授予的激励对象符合《管理办法》《上海证券交易所科创板股票上市规则》等文 件规定的激励对象条件，符合《激励计划（草案）》规定的激励对象条件。本次激励计划首次授予的激 励对象不包括公司监事、独立董事。 综上，公司监事会认为，本次激励计划首次授予的激励对象均符合相关法律、法规及规范性文件所规定 的条件，符合《激励计划（草案）》规定的激励对象条件，其作为本次激励计划首次授予的激励对象合 1、本次激励计划首次授予的激励对象具备《中华人民共 ...

江苏吉贝尔药业股份有限公司 监事会关于公司 2025 年限制性股票激励计划首次授 予激励对象名单审核及公示情况的说明 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏吉贝尔药业股份有限公司（以下简称"公司"）于 2025 年 3 月 28 日召 开第四届董事会第十四次会议、第四届监事会第十三次会议，审议通过了《公司 2025 年限制性股票激励计划（草案）及摘要》等相关议案。根据《上市公司股 权激励管理办法》（以下简称"《管理办法》"）的相关规定，公司对 2025 年限 制性股票激励计划（以下简称"本次激励计划"）首次授予的激励对象名单在公 司内部进行了公示。公司监事会结合公示情况对首次授予的激励对象名单进行了 核查，相关公示情况及核查情况如下： 一、公示情况 1、公司于 2025 年 3 月 29 日在上海证券交易所网站（www.sse.com.cn）上 披露了《江苏吉贝尔药业股份有限公司 2025 年限制性股票激励计划（草案）》（以 下简称"《激励计划（草案）》"）及摘要、《江苏吉贝尔药业股份有限公司 2025 年限制 ...

证券代码：688566 证券简称：吉贝尔 公告编号：2025-010 江苏吉贝尔药业股份有限公司 重要内容提示： ● 大股东持有股份的基本情况 南通汇吉科技发展有限公司(以下简称"汇吉科技")持有江苏吉贝尔药业股份有限公司(以下简称"公司") 股份16,320,000股，占公司总股本的8.18%，前述股份来源于公司首次公开发行前持有的股份，已于 2021年5月18日开市起上市流通。 ● 减持计划的实施结果情况 2024年12月20日，公司披露了《江苏吉贝尔药业股份有限公司关于持股5%以上股东减持股份计划公 告》（公告编号：2024-062），汇吉科技计划通过竞价交易方式减持不超过620,000股其所持有的公司 股份，占公司总股本不超过0.31%，减持期间为2025年1月14日至2025年4月11日，减持价格按市场价格 确定。 公司收到股东汇吉科技出具的《股份减持结果告知函》，截至2025年4月3日收市，汇吉科技通过集中竞 价方式累计减持公司股份620,000股，占公司总股本的0.31%。 一、减持主体减持前基本情况 关于持股5%以上股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何 ...